Want to see CH:SKAN full AI Analyst Report?
Top Page
SKAN Group AG
(SKAN)
Select Model
Select Model
Rating:57Neutral
Price Target:
CHF68.00
▲(3.50% Upside)
Action:Reiterated
Date:07/05/26
The score is primarily driven by solid underlying business performance (strong revenue growth and high gross margins) but is held back by weaker 2025 profitability and a sharp increase in leverage. Technically, momentum is constructive, though overbought readings add near-term risk. Valuation is a meaningful headwind due to a very high P/E and a low dividend yield.
Positive Factors
Strong Revenue Growth
Strong top-line expansion indicates sustained demand for SKAN’s aseptic manufacturing systems, supported by pharmaceutical capacity investment, contamination-control needs, and customer production expansion.
Negative Factors
Sharp Leverage Increase
The abrupt increase in leverage, alongside lower equity, materially reduces financial flexibility. Higher debt obligations can constrain investment and amplify the impact of weaker profitability or execution issues across cyclical customer projects.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Strong top-line expansion indicates sustained demand for SKAN’s aseptic manufacturing systems, supported by pharmaceutical capacity investment, contamination-control needs, and customer production expansion.
Read all positive factors
SKAN Group AG (SKAN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF1.45B
Dividend Yield0.34%
Average Volume (3M)36.56K
Price to Earnings (P/E)48.5
Beta (1Y)1.02
Revenue Growth9.37%
EPS Growth85.35%
CountryCH
Employees1,694
SectorGeneral
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.33
Shares Outstanding22,483,524
10 Day Avg. Volume35,580
30 Day Avg. Volume36,560
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)10.37
Price to Sales (P/S)3.56
P/FCF Ratio56.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.33
Revenue Forecast (FY)CHF395.52M
SKAN Group AG Business Overview & Revenue Model
Company Description
SKAN Group AG is a global leader specializing in critical solutions for the pharmaceutical and chemical sectors, offering advanced isolators, cleanroom technologies, and decontamination processes across Asia, Europe, and the Americas. The company ...
How the Company Makes Money
SKAN primarily makes money by selling engineered equipment and complete systems to pharmaceutical and biotechnology manufacturers and by providing recurring services over the installed base.
1) Capital equipment and project-based system sales: A ...
SKAN Group AG Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
52
Neutral
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 363.25M | 333.33M | 361.30M | 320.02M | 276.95M | 234.26M |
| Gross Profit | 251.20M | 230.31M | 265.88M | 234.08M | 200.50M | 170.11M |
| EBITDA | 58.38M | 36.03M | 59.68M | 50.14M | 40.15M | 32.38M |
| Net Income | 29.98M | 16.27M | 38.80M | 26.31M | 18.99M | 10.62M |
Balance Sheet | ||||||
| Total Assets | 480.03M | 481.08M | 384.49M | 373.45M | 388.35M | 331.92M |
| Cash, Cash Equivalents and Short-Term Investments | 88.47M | 94.08M | 61.71M | 85.12M | 135.98M | 131.54M |
| Total Debt | 130.63M | 131.47M | 10.61M | 6.49M | 16.88M | 15.27M |
| Total Liabilities | 354.55M | 353.49M | 181.92M | 197.09M | 222.76M | 157.92M |
| Stockholders Equity | 113.67M | 114.45M | 196.16M | 169.23M | 157.30M | 159.75M |
Cash Flow | ||||||
| Free Cash Flow | 21.52M | 21.01M | -7.09M | -26.60M | 32.62M | -32.29M |
| Operating Cash Flow | 57.85M | 64.11M | 46.70M | 8.70M | 61.48M | 10.32M |
| Investing Cash Flow | -131.16M | -130.91M | -69.06M | -17.35M | -76.42M | -11.02M |
| Financing Cash Flow | 110.64M | 108.99M | -9.35M | -15.80M | -4.85M | 67.48M |
SKAN Group AG Technical Analysis
Positive
65.70
Price Trends
59.47
Positive
54.09
Positive
52.27
Positive
Market Momentum
1.91
Positive
60.29
Neutral
41.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SKAN, the sentiment is Positive. The current price of 65.7 is above the 20-day moving average (MA) of 62.86, above the 50-day MA of 59.47, and above the 200-day MA of 52.27, indicating a bullish trend. The MACD of 1.91 indicates Positive momentum. The RSI at 60.29 is Neutral, neither overbought nor oversold. The STOCH value of 41.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:SKAN.
SKAN Group AG Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | CHF265.27M | 9.64 | 11.74% | 3.70% | -1.24% | -11.13% | |
71 Outperform | CHF1.33B | 25.29 | ― | 1.99% | 1.72% | -9.57% | |
67 Neutral | CHF1.94B | 73.55 | ― | 2.39% | 2.60% | -65.24% | |
63 Neutral | CHF2.50B | -21.28 | -10.25% | 1.54% | -3.98% | -284.91% | |
57 Neutral | CHF1.45B | 48.50 | ― | 0.34% | 9.37% | 85.35% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | CHF370.12M | 3,588.00 | ― | 1.11% | -6.64% | ― |
* General Sector Average
CH:SKAN
SKAN Group AG
64.50
6.67
11.53%
CH:KARN
Kardex AG
251.00
-65.05
-20.58%
CH:INRN
Interroll Holding AG
1,606.00
-704.79
-30.50%
CH:MIKN
Mikron Holding AG
16.20
-1.57
-8.86%
CH:TECN
Tecan Group AG
194.90
41.66
27.19%
CH:MEDX
medmix AG
8.97
-1.43
-13.78%
SKAN Group AG Corporate Events
SKAN lifts first-half sales and profit, confirms 2026 guidance
Aug 18, 2026
SKAN reported a strong first half of 2026, with order intake up 16.3% to CHF 247.6 million and net sales rising 22.2% to CHF 164.5 million, driven by robust demand and recent acquisitions. Profitability rebounded sharply as EBITDA climbed to CHF 1...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.